NEW YORK & DALLAS--(BUSINESS WIRE)--
Lev Pharmaceuticals, Inc. (OTC Bulletin Board: LEVP) today announced that investigators presented results from a pivotal, Phase III trial of Cinryze™ (C1 inhibitor), in patients with acute attacks of hereditary angioedema (HAE), also known as C1 Inhibitor Deficiency, a genetic condition that causes recurrent and potentially-life threatening inflammation in the larynx, abdomen, face, extremities and urogenital tract. The results were presented at the 2007 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Dallas.
